02:14USA: Martin Shkreli silenced by new lawyer Ben Brafman
Former Turing Pharmaceuticals CEO Martin Shkreli was silenced by his lawyer on entering the courthouse in Brooklyn, Wednesday. Lawyer Ben Brafman also spoke for him when they re-emerged.
He said that his client will not "speak to any member of the press at all until the criminal charges are resolved." and that they "want to try this case in the courtroom and not in the media."
Brafman dubbed the case "very defensible" and that the defence team does "not believe that Mr. Shkreli ever knowingly violated the law or intended to defraud anyone." Brafman also denied the possible connection between the ongoing case against Shkreli and the Daraprim controversy.
Brafman went on to add that should Shkreli be invoked to appear before a congressional committee, he would most likely "be invoking his Fifth Amendment privilege against self-incrimination and not answering any questions."
The thirty-two year old Shkreli made global headlines in 2015 after the pharmaceutical company he founded, Turing Pharmaceuticals, secured the U.S. rights to sell a reportedly life-saving medicine called Daraprim for $55 million (€49,5 million) and raised the price from $13.50 (€12.15) to $750 (€675) per pill shortly afterwards.
02:14Former Turing Pharmaceuticals CEO Martin Shkreli was silenced by his lawyer on entering the courthouse in Brooklyn, Wednesday. Lawyer Ben Brafman also spoke for him when they re-emerged.
He said that his client will not "speak to any member of the press at all until the criminal charges are resolved." and that they "want to try this case in the courtroom and not in the media."
Brafman dubbed the case "very defensible" and that the defence team does "not believe that Mr. Shkreli ever knowingly violated the law or intended to defraud anyone." Brafman also denied the possible connection between the ongoing case against Shkreli and the Daraprim controversy.
Brafman went on to add that should Shkreli be invoked to appear before a congressional committee, he would most likely "be invoking his Fifth Amendment privilege against self-incrimination and not answering any questions."
The thirty-two year old Shkreli made global headlines in 2015 after the pharmaceutical company he founded, Turing Pharmaceuticals, secured the U.S. rights to sell a reportedly life-saving medicine called Daraprim for $55 million (€49,5 million) and raised the price from $13.50 (€12.15) to $750 (€675) per pill shortly afterwards.